[company_age]3.0[/company_age][employees]1 employee[/employees][description]Novavido, an Italian startup founded in 2021, is pioneering a revolutionary approach to vision restoration for retinitis pigmentosa patients. Their groundbreaking liquid retina technology, developed in collaboration with the Italian Institute of Technology and the IRCCS Sacro Cuore Don Calabria Hospital, has the potential to replace damaged photoreceptors and restore sight across the entire visual field. This sets them apart from traditional methods that often focus on specific areas or require invasive procedures. Novavido's liquid retina has demonstrated remarkable efficacy in pre-clinical trials, restoring vision in a retinitis pigmentosa model for up to 9 months after implantation. This promising technology has garnered significant attention, with features in Panorama magazine and presentations at G-Factor's demo day. Led by CEO Giovanni Manfredi, Guglielmo Lanzani, and Fabio Benfenati, Novavido is dedicated to bringing this revolutionary treatment to patients worldwide.[/description][ps]Liquid retina implant for vision restoration in patients with retinitis pigmentosa.[/ps]